Halo's lead program, H01, is a small-molecule first-in-class inhibitor of HA synthesis under development for conditions including pulmonary hypertension, IPF, and primary sclerosing cholangitis. A Phase I study was recently completed at Stanford University.
Our pipeline of proprietary compounds targeting extra cellular matrix editing are in various stages of discovery and preclinical development. Our partnership with Stanford University and the Paul Bollyky Lab serves as the anchor for drug candidate discovery and lead optimization.
Extracellular matrix editing represents a novel, differentiated mechanism with potential to transform disease states
Halo is a team of leaders in extracellular matrix biology and drug development. We are closely connected to Stanford University's unparalleled ecosystem of drug discovery.
Learn more about Halo, our pipeline, and extracellular matrix editing
Copyright © 2022 Halo Biosciences - All Rights Reserved.